FOllow-up of LOW-acuity Patients After REdirection From a Swiss Emergency Department Using an Electronic TRIage Application
Launched by HÔPITAL FRIBOURGEOIS · May 6, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new electronic system designed to help manage patients with non-urgent health issues who visit the emergency department (ED). The goal is to see if using this new system can reduce the number of follow-up visits to the ED within 48 hours of the first visit. The study will compare the current method of triage, which only redirects low-acuity patients (those with less serious conditions), to the new system that also includes semi-urgent patients (those who may need care soon but not immediately). By improving how patients are directed to appropriate care, the trial hopes to make the healthcare process smoother and safer for everyone involved.
To participate in this trial, individuals must be 18 years or older, have been classified as low-acuity or semi-urgent based on a specific scale, and be able to communicate in French or German. Participants will receive follow-up phone calls and questionnaires over a six-month period to track their health care experiences and satisfaction. It's important to note that those who cannot provide consent or who have certain health conditions may not be eligible. Overall, this study aims to enhance patient care and accessibility while ensuring that patients receive the right level of attention for their health needs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years old
- • Triage level SETS 3 or SETS 4 (classified as semi-urgent or low-acuity)
- • Identified as eligible for redirection by the Logibec electronic triage system
- • Able to speak and read French or German (for informed consent and follow-up)
- • Provides informed consent: Oral consent at Day 2 and Signed informed consent sent by post after inclusion
- Exclusion Criteria:
- • Inability to provide informed consent (e.g., cognitive impairment, language barrier without translation support)
- • Inability to comply with study procedures, such as: Severe hearing impairment without hearing aids; Acute psychiatric conditions preventing participation; Not available for follow-up phone calls within the next 6 months
About Hôpital Fribourgeois
Hôpital Fribourgeois is a leading healthcare institution located in Fribourg, Switzerland, dedicated to providing high-quality medical care and advancing clinical research. As a sponsor of clinical trials, Hôpital Fribourgeois is committed to exploring innovative treatments and therapies that enhance patient outcomes. The hospital's multidisciplinary team of experienced researchers and healthcare professionals collaborates closely with academic and industry partners to ensure the rigorous design and ethical conduct of clinical studies. Through its research initiatives, Hôpital Fribourgeois aims to contribute significantly to medical knowledge and improve healthcare practices both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fribourg, , Switzerland
Patients applied
Trial Officials
Vincent Ribordy, Prof.
Study Director
HFR-Fribourg Emergency Department, University of Fribourg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported